San­thera en­ters li­cense agree­ment with Chiesi Group; Tonix's co­caine in­tox­i­ca­tion drug, Io­vance's cer­vi­cal can­cer treat­ment win FDA's break­through sta­tus

→ Swiss-based San­thera has en­tered an ex­clu­sive glob­al — ex­cept for the US and Cana­da— li­cense agree­ment with in­ter­na­tion­al re­search-fo­cused health­care group Chiesi Far­ma­ceu­ti­ci. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER